









Markets
/
Stocks
/
nasdaq-clnn
/

Clene Inc.

CLNN

4.290USD

+0.370+9.44%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

43.84MMarket Cap

LossP/E TTM



Clene Inc.

4.290

+0.370+9.44%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Clene Inc.

Currency: USD Updated: 2026-02-06

Key Insights

Clene Inc.'s fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 171 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 31.86.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Clene Inc.'s Score

Industry at a Glance

Industry Ranking

171 / 392

Overall Ranking

323 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Clene Inc. Highlights

StrengthsRisks

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.

Growing

The company is in a growing phase, with the latest annual income totaling USD 342.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 342.00K.

Fairly Valued

The company’s latest PE is -1.25, at a medium 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 222.91K shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

31.857

Target Price

+712.68%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Clene Inc. is 5.51, ranking 354 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 15.00K, representing a year-over-year decrease of 82.76%, while its net profit experienced a year-over-year decrease of 9.90%.

Score

Industry at a Glance

Previous score

5.51

Change



Financials

5.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.95

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.62

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Clene Inc.'s Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Clene Inc. is 6.35, ranking 291 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.25, which is -120.44% below the recent high of 0.25 and -5567.74% above the recent low of -70.61.

Score

Industry at a Glance

Previous score

6.35

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 171/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Clene Inc. is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 48.00 and a low of 23.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

31.857

Target Price

+712.68%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Clene Inc.

CLNN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Clene Inc. is 6.51, ranking 230 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.02 and the support level at 3.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.28

Change

0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.031

Sell

RSI(14)

38.475

Neutral

STOCH(KDJ)(9,3,3)

18.371

Neutral

ATR(14)

0.424

High Vlolatility

CCI(14)

-60.778

Neutral

Williams %R

73.548

Sell

TRIX(12,20)

-1.503

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

4.102

Buy

MA10

4.394

Sell

MA20

4.827

Sell

MA50

6.038

Sell

MA100

7.256

Sell

MA200

5.600

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Clene Inc. is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 21.16%, representing a quarter-over-quarter decrease of 18.34%. The largest institutional shareholder is The Vanguard, holding a total of 222.91K shares, representing 2.05% of shares outstanding, with 33.56% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Mosca (Alison)

1.31M

+231.66%

General Resonance, L.L.C.

704.59K

-0.48%

SymBiosis Capital Management, LLC

650.95K

Matlin (David J.)

451.99K

-0.00%

Scoggin Management LP

250.00K

+75.13%

The Vanguard Group, Inc.

Star Investors

200.98K

+6.70%

4life Research, L.L.C.

199.84K

-0.00%

Kensington Investments, L.P.

150.33K

Gay (Jonathon)

116.46K

-0.00%

Geode Capital Management, L.L.C.

75.99K

+11.21%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Clene Inc. is 1.57, ranking 303 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.68. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Clene Inc.’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.